Showing 1 - 20 results of 1,099 for search '(( 5 i decrease ) OR ((((( _ we decrease ) OR ( a al decrease ))) OR ( _ e decrease ))))', query time: 0.22s Refine Results
  1. 1

    Decreased methylglyoxal-mediated protein glycation in the healthy aging mouse model of ectopic expression of UCP1 in skeletal muscle by Jinit, Masania

    Published 2023
    “…We found both young and aged HSA-mUCP1 mice had decreased advanced glycation endproducts (AGEs) formed from MG, lysine-derived Nε(1-carboxyethyl)lysine (CEL) and arginine-derived hydroimidazolone, MG-H1, whereas protein glycation by glucose forming Nε-fructosyl-lysine (FL) was increased ca. 2-fold, compared to wildtype controls. …”
    Get full text
    Get full text
    Get full text
    article
  2. 2

    Decreased methylglyoxal-mediated protein glycation in the healthy aging mouse model of ectopic expression of UCP1 in skeletal muscle by Jinit Masania (7164239)

    Published 2023
    “…We found both young and aged HSA-mUCP1 mice had decreased advanced glycation endproducts (AGEs) formed from MG, lysine-derived Nε(1-carboxyethyl)lysine (CEL) and arginine-derived hydroimidazolone, MG-H1, whereas protein glycation by glucose forming Nε-fructosyl-lysine (FL) was increased ca. 2-fold, compared to wildtype controls. …”
  3. 3

    Decreased Interfacial Dynamics Caused by the N501Y Mutation in the SARS-CoV-2 S1 Spike:ACE2 Complex by Wesam S. Ahmed (10170053)

    Published 2022
    “…By elucidating a mechanistic basis for the increased affinity of the N501Y mutant S1-RBD for ACE2, we believe that the results presented here will aid in developing therapeutic strategies against SARS-CoV-2 including designing of therapeutic agents targeting the ACE2-S1-RBD interaction.…”
  4. 4

    Corrigendum: Decreased interfacial dynamics caused by the N501Y mutation in the SARS-CoV-2 S1 spike:ACE2 complex by Wesam S. Ahmed (10170053)

    Published 2022
    “…<p dir="ltr">Corrigendum: Decreased interfacial dynamics caused by the N501Y mutation in the SARS-CoV-2 S1 spike:ACE2 complex: Frontiers in Molecular Biosciences <a href="https://dx.doi.org/10.3389/fmolb.2022.846996" target="_blank">https://dx.doi.org/10.3389/fmolb.2022.846996</a>, published online 22 July 2022.…”
  5. 5
  6. 6

    Notch Signaling Inhibition by LY411575 Attenuates Osteoblast Differentiation and Decreased Ectopic Bone Formation Capacity of Human Skeletal (Mesenchymal) Stem Cells by Nihal AlMuraikhi (6002234)

    Published 2019
    “…Among the affected signaling networks were TGFβ1, SPP1, and ERK regulatory networks. Conclusions. We identified γ-secretase inhibitor (LY411575) as a potent regulator of osteoblastic differentiation of hBMSC that may be useful as a therapeutic option for treating conditions associated with ectopic bone formation.…”
  7. 7

    A slow but steady nanoLuc: R162A mutation results in a decreased, but stable, nanoLuc activity by Wesam S. Ahmed (10170053)

    Published 2024
    “…However, questions related to its mechanism of interaction with the substrate, furimazine, as well as bioluminescence activity remain elusive. Here, we combined molecular dynamics (MD) simulation and mutational analysis to show that the R162A mutation results in a decreased but stable <u>bioluminescence </u>activity of NLuc in living cells and in vitro. …”
  8. 8
  9. 9
  10. 10

    Assessment of aged biodegradable polymer-coated nano-zero-valent iron for degradation of hexahydro-1,3,5-trinitro-1,3,5-triazine (RDX) by Wazne, Mahmoud

    Published 2012
    “…BACKGROUND: This study reports on the effects of aging on suspension behavior of biodegradable polymer-coated nano-zero-valent iron (nZVI) and its degradation rates of hexahydro-1,3,5-trinitro-1,3,5-triazine (RDX) under reductive conditions. …”
    Get full text
    Get full text
    article
  11. 11

    Follow up and comparative assessment of IgG, IgA, and neutralizing antibody responses to SARS-CoV-2 between mRNA-vaccinated naïve and unvaccinated naturally infected individuals ov... by Salma, Younes

    Published 2023
    “…We measured the levels of neutralizing total antibodies (NtAbs), anti-S-RBD IgG, and anti-S1 IgA titers among VN and NI up to ∼10 months from administration of the first dose, and up to ∼7 months from SARS-CoV-2 infection, respectively. …”
    Get full text
    Get full text
    Get full text
    article
  12. 12

    Effects of vitamin E derivatives on the proliferation of KG-1 leukemic cells in vitro by Rizk, Sandra

    Published 2017
    “…XTT cell viability assay, which detects the presence of metabolically active cells, was used to assess cell proliferation. A decrease in proliferation of KG-1 cells was observed upon treatment with both forms of vitamin E derivatives; however, β-T3 was more potent than γ-T3 in promoting cell death with lower IC50 values. …”
    Get full text
    Get full text
    Get full text
    article
  13. 13

    Decreased phosphodiesterase activities in cardiac hypertrophy by Abi-Gerges, A.

    Published 2007
    “…There is limited information on the changes in cardiac cyclic nucleotide phosphodiesterases (PDE1 to PDE5) during hypertrophy and the functional consequences on the cAMP pathway. …”
    Get full text
    Get full text
    Get full text
    Get full text
    article
  14. 14

    Follow up and comparative assessment of IgG, IgA, and neutralizing antibody responses to SARS-CoV-2 between mRNA-vaccinated naïve and unvaccinated naturally infected individuals ov... by Salma Younes (6424865)

    Published 2023
    “…We measured the levels of neutralizing total antibodies (NtAbs), anti-S-RBD IgG, and anti-S1 IgA titers among VN and NI up to ∼10 months from administration of the first dose, and up to ∼7 months from SARS-CoV-2 infection, respectively. …”
  15. 15
  16. 16

    Soluble Neuropilin-1 Response to Hypoglycemia in Type 2 Diabetes: Increased Risk or Protection in SARS-CoV-2 Infection? by Abu Saleh Md Moin (6189512)

    Published 2021
    “…<h3>Introduction</h3><p dir="ltr">Neuropilin-1(NRP1) is a cofactor that enhances SARS-CoV-2 coronavirus cell infectivity when co-expressed with angiotensin-converting enzyme 2(ACE2). …”
  17. 17
  18. 18
  19. 19

    LDL-C Targets in Secondary Prevention: How Low Should We Go? by Karim Bayoumy (3496688)

    Published 2019
    “…<h3>Abstract</h3><p dir="ltr">The benefits of lowering low-density lipoprotein cholesterol (LDL-C), mainly using high-intensity statin therapy, and its impact on decreasing the recurrence of atherosclerotic cardiovascular disease (ASCVD) in secondary prevention has been well established. …”
  20. 20